RecruitingNCT06026488
Real-World Study of DLBCL With Different Genetic Subtypes
A Real-World Study of Diffuse Large B-Cell Lymphoma (DLBCL) Patients With Different Genetic Subtypes
Sponsor
Ruijin Hospital
Enrollment
10,000 participants
Start Date
Oct 1, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
To collect and evaluate the data of real-world treatment regimen, efficacy, safety and survival information of DLBCL patients with different genetic suptypes
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Histologically-confirmed diffuse large B-cell lymphoma (DLBCL)
- Genetic subtype belonging to at least one of the seven subtypes by using next generation sequencing: MCD, BN2, N1, ST2, A53, EZB (MYC+, MYC-) and others
- Fully comprehension and signature of the informed consent form (ICF) for participation
Exclusion Criteria3
- Those who refuse to use reliable methods of contraception during pregnancy, lactation or age-appropriate period
- Severe mental illness
- Patients deemed unsuitable for inclusion by the investigator
Interventions
OTHEROther
real world treatment and survival of DLBCL patients in China
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06026488
Related Trials
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
NCT0685942413 locations
CAR-T Followed by Bispecific Antibodies
NCT048897162 locations
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
NCT0233266817 locations
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
NCT065103091 location
Odronextamab in Low Tumor Volume Advanced FL
NCT071286411 location